Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 517 across all filing types
Latest filing 2021-04-27 AGM Information
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Notice of annual general meeting in Cantargia AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Notice of annual general meeting in Cantargia AB (publ)" and details the procedures for shareholders to participate via advance voting, the proposed agenda items (including election of chairman, approval of minutes, resolutions on financial statements, election of board members and auditor), and proposals regarding remuneration and incentive schemes. These elements are characteristic of materials distributed to shareholders in preparation for an Annual General Meeting (AGM). The code AGM-R (AGM Information) is the most appropriate classification, as it covers presentations and materials shared during the AGM.
2021-04-27 English
Cantargia presenterar nya prekliniska resultat kring antikroppen CAN10 på IMMMUNOLOGY2021
Regulatory Filings Classification · 99% confidence The document is a 'Pressmeddelande' (Press Release) from Cantargia AB dated April 26, 2021. It announces that new preclinical results regarding the antibody CAN10 will be presented at the IMMUNOLOGY2021 scientific conference. The text details the scientific findings and mentions that the summary is published on the conference website. Crucially, it is an announcement about future presentation of data, not the full report itself (like 10-K or IR). Since it is a general announcement regarding company news and scientific updates that doesn't fit the specific categories like Earnings Release (ER), Director's Dealing (DIRS), or Capital Change (CAP), it falls best under the general Regulatory Filings category (RNS) as a miscellaneous regulatory announcement, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is just the announcement of the presentation. Given the nature of a press release announcing scientific data presentation, RNS is the most appropriate fallback for non-standard regulatory disclosures.
2021-04-26 Swedish
Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
Regulatory Filings Classification · 99% confidence The document is titled 'Press release' and announces that new preclinical data on the antibody CAN10 will be presented at the IMMMUNOLOGY2021 scientific conference. It details the scientific findings and mentions that the abstract has been published. The text concludes with a statement that this information is made public pursuant to the EU Market Abuse Regulation and is dated April 26, 2021. This structure—a brief announcement about upcoming presentation of scientific data, often referencing an abstract or publication—is characteristic of a general regulatory announcement or press release that doesn't fit a specific financial report category like 10-K, ER, or IR. Since it is a general announcement regarding company activity (data presentation) and is not a core financial report, the most appropriate general category is Regulatory Filings (RNS), as it serves as a catch-all for non-standard regulatory disclosures.
2021-04-26 English
Cantargia reports positive preclinical safety and efficacy results in the CAN10 project
Earnings Release Classification · 99% confidence The document is titled 'Press release' and announces positive preclinical safety and efficacy results for a drug candidate (CAN10) and provides updates on another (CAN04). It includes financial/development milestones and is dated March 19, 2021. Crucially, it ends with the statement: 'This is information that Cantargia AB is obliged to make public pursuant to the EU Market Abuse Regulation.' This strongly indicates a mandatory regulatory disclosure, but it is not a formal SEC filing like a 10-K, nor is it a detailed financial report (IR/ER). It is an announcement of operational/scientific progress. Since it is a general regulatory announcement that doesn't fit the specific categories like ER (Earnings Release), IR (Interim Report), or DIV (Dividend Notice), the most appropriate general regulatory category is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on preclinical data, not period financial results. Q2 2021
2021-03-19 English
Cantargia rapporterar positiva prekliniska resultat kring säkerhet och effekt i CAN10-projektet
Earnings Release Classification · 99% confidence The document is a press release ("Pressmeddelande") dated March 19, 2021, announcing positive preclinical results for the drug candidate CAN10 regarding safety and efficacy in treating myocarditis and systemic sclerosis. It details study outcomes, toxicology results, and future development plans (clinical trials starting in 2022). The text explicitly states that the information is being made public under the EU Market Abuse Regulation ("EU:s marknadsmissbruksförordning"). This type of announcement, which releases material, non-financial, or preliminary scientific/development updates outside of scheduled financial reports (like 10-K or IR), typically falls under general regulatory announcements or investor relations updates. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change, it best fits the category for general regulatory announcements or investor news. Given the content is a scientific/development update intended for investors, and it is not a formal presentation (IP) or a short notice about a report (RPA), the most appropriate general category for such a significant, non-scheduled update is Regulatory Filings (RNS), which serves as a broad category for mandatory disclosures that don't fit elsewhere, especially when mandated by market abuse rules. It is not a Call Transcript (CT), Director's Dealing (DIRS), or Dividend Notice (DIV). Q2 2021
2021-03-19 Swedish
Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer
Legal Proceedings Report Classification · 99% confidence The document is a press release (Pressmeddelande) from Cantargia AB dated March 10, 2021. It announces that the company has submitted an application for a new clinical study investigating the antibody CAN04 in combination with FOLFIRINOX for pancreatic cancer. It details the study design, patient numbers, locations (France and Spain), and expected start time (Q2 2021). It also includes background information on the drug, previous studies, and quotes from the CEO. This type of announcement, detailing a specific corporate action related to clinical development and strategy, is best classified as an Investor Presentation (IP) if it were a detailed deck, or more generally, a Regulatory Filing (RNS) if it were a standard regulatory disclosure. However, given the content focuses heavily on clinical trial updates, drug development pipeline, and strategic progress, it aligns closely with materials provided to investors to inform them of operational milestones. Since there is no specific category for 'Clinical Trial Application Announcement' and it is not a formal financial report (10-K, IR, ER), nor a general regulatory filing (RNS), the closest fit among the provided options that covers strategic operational updates, especially in the biotech sector, is Investor Presentation (IP), as these press releases often serve that function when detailing pipeline progress. Alternatively, since it is a formal announcement of a significant corporate/operational event, RNS (Regulatory Filings) is a strong fallback. Given the detailed nature of the clinical update, IP is slightly more descriptive of the content's purpose than the generic RNS, but RNS is the safest catch-all for non-standard announcements. Since it is a press release announcing a specific operational step (filing for a new trial), and not a general regulatory filing, I will lean towards RNS as the most appropriate general category for non-standard corporate news releases that don't fit ER, IR, or CAP.
2021-03-10 Swedish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.